Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Colonoscopy
Interventions: BLI4700, Polyethylene glycol bowel preparation; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 23
States / cities: Mobile, Alabama • Tucson, Arizona • Anaheim, California + 20 more

Conditions: Organ Donation
Interventions: Control ending - Uplifting, Negative Consequences Ending, Unresolved Ending; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 1,440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: recMAGE-A3 Protein + AS15 Adjuvant; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Preterm Infant Health, Premature Babies
Interventions: Human Milk Concentration Device, Standard of Care Fortified Feeding; Device · Other
Lead sponsor: Mother's Milk is Best; Industry
Eligibility: 32 Weeks to 35 Weeks
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Phantom Pain
Interventions: Pregabalin, Ketamine, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Zika Virus, Congenital Zika Syndrome, Congenital Infection, Child Development
Interventions: Neurodevelopmental assessments; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 7 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Relacorilant, Nab-paclitaxel; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more

Conditions: Pre-Eclampsia
Interventions: ARTSENS Pen; Device
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glioma
Interventions: bevacizumab, carmustine; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: COVID-19
Interventions: Shionogi Protease Inhibitor (S-217622), placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 103
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: Carl Weiner, MD; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 431 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Cardiovascular Disease, Metabolic Syndrome, Obesity
Interventions: Low-Fat Milk, Rice Milk; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Breast Cancer
Interventions: Standard Dose Dense Doxorubucin and Cyclophosphamide, Standard Doxorubucin and Cyclophosphamide, Standard Docetaxel, Carboplatin, and Herceptin, Standard Docetaxel, Doxorubucin and Cyclophosphamide, Standard Docetaxel and Cyclophosphamide; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depression and Suicide, Mood Disorders, Other Perinatal Conditions
Interventions: Not listed
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Grand Rapids, Michigan

Conditions: Sickle Cell Disease
Interventions: Red Blood Cell, Standard of care; Biological · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 20
States / cities: Tuscaloosa, Alabama • Oakland, California • Washington D.C., District of Columbia + 15 more

Conditions: Joint Replacement Surgery
Interventions: Dummy Movements, Psychosensory Therapy; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Noise-induced Hearing Loss
Interventions: Interactive youth educational program, Internet-based educational booster; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 8 Years to 12 Years
Enrollment: 2,093 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pulmonary Disease, Chronic Obstructive (COPD), Cognitive Impairment
Interventions: Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk Test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI; Behavioral · Procedure · Diagnostic Test + 1 more
Lead sponsor: Karin Hoth; Other
Eligibility: 30 Years to 85 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hearing Loss
Interventions: Clinically Streamlined and Structured Aural Rehabilitation (CSSAR); Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 55 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity
Interventions: Ensure and Water; Other
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Arrythmia, Cardiomyopathies
Interventions: Intra-Op Prophylactic VT ablation, Conventional Management; Procedure · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Induced Abortion, Abortion Techniques, Mifepristone, Misoprostol
Interventions: Mifepristone, Misoprostol; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma
Interventions: G-CSF and plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 5
States / cities: Duarte, California • Beech Grove, Indiana • Rochester, New York + 2 more

Conditions: Pancreatic Cancer
Interventions: PEGPH20, Cetuximab, DW & DCE-MRI, blood draws; Drug · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Safety and Efficacy Comparison of BLI4700 Bowel Prep Versus an FDA-approved Comparator in Adults Prior to Colonoscopy

RCT- Comparing Testimonial Versus Documentary Organ Donation Video Education

MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Human Milk Concentrating Device to Optimize Mother's Own Milk

Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain

Neurodevelopmental Outcomes in ZIKV-Exposed Children

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Prospective Case-Control Study of Cardiovascular Changes in Pregnancy Related Hypertensive Disorders

Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk

Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome

Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens

Biological Triggers of Depression in Pregnancy

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

The Effect of a Psychosensory Therapy

Test of Hearing Health Education Programs for Farm and Rural Youth

COPD-Related Physiology and the Brain

Benefit of a Clinically Streamlined and Structured Aural Rehabilitation (CSSAR) Program in Adults

A Translational Understanding of Obesity-Related Phenotypes Using Brain Imaging and Manipulation

The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection